Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(66.7%)
N/A
1(33.3%)
3Total
Phase 1(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07400289Not ApplicableRecruiting

Development of a FibroScan Liver Examination Using a Single Probe

Role: collaborator

NCT06698861Phase 1Completed

A Phase I PK/PD Study of PEG-MetHuG-CSF (P2203) in Healthy Volunteers

Role: collaborator

NCT05712538Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of ARCT-032 in Healthy Adult Subjects and Adults With Cystic Fibrosis.

Role: collaborator

All 3 trials loaded